A study to evaluate the effects of a drug(Dexmedetomidine) in patients undergoing brain surgery for Brain Tumors

Bi Spectral Index(BIS) guided evaluation of dexmedetomidine as anaesthetic adjunct in patients undergoing craniotomy and excision of space occupying lesion

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/09/009892

Enrollment

Registered

2017-09-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patiwnts with space occupying lesion(brain tumor) 18 to 60 years of age male or female ASA grade 1 or 2

Interventions

Intervention1: dexmedetomidine: drug will be given at two doses. 1st dose - as a loading dose of 0.5ug/kg intra venously in 10 minutes before start of surgery. 2nd dose -dexmedetomidine infusion given

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis - Space Occupying Lesion(brain tumor) 2. Glasgow Coma Scale score > 12 3. Duration of surgery 4 to 5 hours 4. ASA grade 1 or 2

Exclusion criteria

Exclusion criteria: 1. Patient not giving consent 2. Coronary Heart Disease 3. Cerebro Vascular Disease 4. Thrombo Embolic Disease 5. Hypertensive patient

Design outcomes

Primary

Measure	Time frame
Haemodynamic Stability Reduced requirement of Isoflurane Reduced requirement of repeat dose of FentanylTimepoint: Haemodynamic Stability Reduced requirement of Isoflurane Reduced requirement of repeat dose of Fentanyl	—

Secondary

Measure	Time frame
Optimum infusion dose Any side effectTimepoint: Intra Operatively	—

Countries

India

Contacts

Public ContactDr Amber Rawat

king george medical university

kohli.mona@gmail.com9839041228

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026